Cite
HARVARD Citation
Hu, S. et al. (2023). Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China. Diabetes, obesity & metabolism. 25 (2), pp. 387-397. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hu, S. et al. (2023). Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China. Diabetes, obesity & metabolism. 25 (2), pp. 387-397. [Online].